New drug cocktail targets brain tumors from lung and breast cancer
NCT ID NCT07449481
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Participants will receive the drugs intravenously in 21-day cycles, continuing as long as they benefit or until side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- utidelone and bevacizumab, with or without etoposide
- What this could lead to
- If successful, this could offer a new drug combination to shrink brain metastases from lung or breast cancer, potentially improving survival and quality of life.
- What could go wrong
- This is an early Phase 2 trial with only 56 participants, so results may not apply broadly. Side effects like nerve damage from utidelone are possible, and the combination may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-ANGIOGENIC TARGETED DRUGS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Ear acupressure: a new weapon against chemotherapy side effects?